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FDG-PET, combined with CT, is nowadays gettingmore andmore relevant for the diagnosis of several infectious and inflammatory
diseases and particularly for therapy monitoring. Thus, this paper gives special attention to the role of FDG-PET/CT in the
diagnosis and therapy monitoring of infectious and inflammatory diseases. Enough evidence in the literature already exists about
the usefulness of FDG-PET/CT in the diagnosis, management, and followup of patients with sarcoidosis, spondylodiscitis, and
vasculitis. For other diseases, such as inflammatory bowel diseases, rheumatoid arthritis, autoimmune pancreatitis, and fungal
infections, hard evidence is lacking, but studies also point out that FDG-PET/CT could be useful. It is of invaluable importance
to have large prospective multicenter studies in this field to provide clear answers, not only for the status of nuclear medicine in
general but also to reduce high costs of treatment.
1. Introduction
In recent years, the use of nuclear medicine to characterize
and diagnose infectious and inflammatory diseases is rapidly
increasing. Several SPECT and PET radiopharmaceuticals
have been developed and applied in this field, radiolabelled
white blood cells being the centerpiece [1]. However, [18F]-
FDG-PET combined with low dose or diagnostic computed
tomography (CT) is gaining interest in the diagnosis of many
infectious and inflammatory diseases and is already the gold
standard for some indications.
The accumulation of FDG in inflammatory and infectious
diseases is based on the high uptake in activated granulocytes.
This accumulation is based on the fact that these cells use
glucose as an energy source only after activation during
the metabolic burst. Transport of FDG across the cellular
membrane is mediated by the glucose transporter (GLUT)
proteins, which are also to a higher amount present on the
cell membrane of inflammatory and infectious cells [2].
For therapy followup, the indication of FDG-PET is less
clear. The European Medicines Agency (EMEA) Commit-
tee for Medicinal Products for Human Use (CHMP) only
mentions the use of FDG for the therapeutic followup of
unresectable alveolar echinococcosis, in which it may be used
in the search for active localizations of the parasite during
medical treatment and after treatment discontinuation [3].
Despite this lack of attention, we think that FDG-PET/CT is
not only valuable for therapy monitoring in some infectious
and inflammatory diseases but could even play a pivotal role
in their management, leading to better drug dosage, proof of
the usefulness of the treatment, and early modification of the
therapeutic strategy.
The literature for this review was collected with PubMed
and Cochrane search using the combination of “FDG,”
“therapy,” “therapy evaluation,” and the specific term for
each inflammatory or infectious disease. The reference lists
of selected articles were checked for additional valuable
literature. This paper summarizes most papers published so
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Figure 1: FDG-PET examples of vasculitis: (a) giant cell arteritis and polymyalgia rheumatica: high FDG uptake in the large vessels (aorta,
subclavian arteries, carotid arteries, iliac arteries, and femoral arteries) accompanied by high uptake in the large joints (shoulders and hips),
(b) Takayasu’s arteritis: high FDG uptake located more centrally (aorta and main branches in the thoracic region) and in this case uptake
in reactive lymph nodes in mediastinum and hili (confirmed by biopsy), and (c) polyarteritis nodosa and polychondritis: high uptake in the
medium- and small-sized arteries (best visible in the legs) accompanied by uptake in the nose, the ears, and the costochondral regions.
far in this field and tries to define the role of FDG-PET/CT for
therapy monitoring in various infectious and inflammatory
diseases.
2. Vasculitis
2.1. FDG-PET/CT and Classification of Vasculitis. Systemic
vasculitis is a multisystem disease characterized by inflam-
mation with infiltration of leukocytes into the blood vessels.
Classification of vasculitis is still unsatisfactory and contro-
versial. Existing classifications—the American College of
Rheumatology criteria [4, 5], theChapelHill ConsensusCon-
ference definitions [6], and the adapted Zeek classification
system [7]—are useful but limited [8]. For nuclear medicine,
the Zeek system is most useful since it reflects dominant
vessel size, in association with antineutrophil cytoplasmic
antibodies (ANCAs).
For diagnosis, CT is useful for showing mural changes,
including wall thickening, calcification, and mural thrombi.
CT angiography (CTA) provides the possibility to reveal
luminal changes, such as stenosis, occlusion, dilatation, and
aneurysms [9]. MRI is probably the best method to evaluate
and reveal structural vascular abnormalities (aneurysms,
stenoses) but does not identify inflammation in structural
normal blood vessels [10]. Because of the limited spatial
resolution of the PET/CT camera, nuclear medicine is most
of the times able to visualize only inflammation of the aorta
and the larger arteries. However, depending on the spatial
resolution of the used camera, it is possible to find FDG
uptake also in smaller arteries, as other studies mentioned
[11–13]. Furthermore, FDG-PET/CT may be able to differen-
tiate between giant cell arteritis (GCA), Takayasu’s arteritis
(TA), and polyarteritis nodosa (PAN).
GCA, also called temporal arteritis, is a granulomatous
inflammation of the aorta and its main branches, most of the
times occurring in patients older than 50 years.The extracra-
nial branches are also involved, especially the temporal artery.
Normally, involvement of the temporal artery is difficult to
see on FDG-PET due to its small diameter, but involvement
of the aorta, subclavian, carotid, and iliac arteries is enough
to settle the diagnosis GCA based on FDG-PET findings.
GCA is often associatedwith polymyalgia rheumatica (PMR),
an inflammatory disease around the joints, causing pain and
stiffness (Figure 1(a)).
Takayasu’s arteritis is more centrally located (therefore
also known as aortic arch syndrome) and mainly affects the
aorta and the main branches in the thoracic region (carotid
arteries, brachiocephalic trunk, subclavian arteries, and the
pulmonary arteries). In the majority, it affects young or
middle-aged woman. An example is shown in Figure 1(b). In
this 14-year-old girl, Takayasu’s arteritis was confirmed by
biopsy, togetherwith inflammatory lymphnodes in themedi-
astinum around the inflamed arteries.
PAN is a vasculitis of the medium and small-sized arter-
ies, which become swollen and damaged by immune cells.
Most cases occur at middle age, but it can affect nearly every-
one. PAN may be associated with polychondritis [14], as
shown in Figure 1(c). On FDG-PET, uptake may be seen in
the smaller arteries, best visible in the extremities.
When choosing between FDG-PET/CT andMRI, it is im-
portant to consider both study-specific and patient-specific
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factors. For FDG-PET/CT, some questions still remain to be
answered, for example, the usefulness of this technique in
patients taking corticosteroids and immunosuppressives [15].
2.2. The Role of FDG-PET/CT in Diagnosing and Evaluating
Therapy in Vasculitis. In the setting of diagnosing vasculitis,
FDG-PET/CT was proven valid and utility of FDG-PET/CT
was found in:
(i) the initial diagnosis of patients suspected of having a
vasculitis, and particularly in patients that presented
with nonspecific symptoms. In GCA, sensitivities
ranging from 77 to 92% and specificities from 89 to
100% were reported [16]. In TA, results were even
better (sensitivity 92%, specificity 100%) [17];
(ii) the identification of areas of increased FDG uptake as
a target site in which a biopsy should best be taken to
obtain a definite diagnosis [18, 19];
(iii) the evaluation of the extent of the disease and
involvement of extracranial sites, with more vascular
involvement found by FDG-PET/CT compared to
MRI imaging and traditional angiography [20, 21].
A correlation was also found with inflammatory
markers as C-reactive protein and erythrocyte sedi-
mentation rate [21].
Many case reports are published that mention a role of
FDG-PET/CT in guiding treatment strategy and evaluating
therapy response. However, only a small number of large
patient studies exist.
Blockmans et al. performed FDG-PET at baseline and
after 3 and 6 months of therapy with corticosteroids in 35
patients with suspected GCA. The FDG-PET at baseline was
positive in 29 patients, leading to a sensitivity of 83%. The
total vascular score ((TVS) a scoring system of 0 to 3 points
in 7 vascular regions using the Meller visual grading scale)
decreased from 7.9 at baseline to 2.4 after 3months of therapy.
No further decrease was found at 6 months. However, in
long-term followup, 18 relapses were found, with the TVS
at baseline of this group of relapsing patients not differing
from the whole patient group. The authors concluded that
FDG-PET is sensitive for detecting GCA and that therapy
evaluation after 3 months is possible without added value of
scanning on a later time point. Relapse of GCA could not be
predicted by FDG-PET [22].
Bertagna et al. performed FDG-PET/CT before and at
least 4 months after corticosteroid therapy in 9 patients
with proven vasculitis. Eight patients became negative after
therapy (aorta/liver ratio < 1 or SUVmax < 2), which was
concordant with clinical and biochemical findings. One
patient remained positive on FDG-PET, which was also
confirmed clinically and biochemically. Using FDG-PET/CT,
instead of FDG-PET alone, allowed the authors to precisely
identify the anatomical sites of disease, which was found
particularly useful after therapy to identify possible weak
persistence of disease. They concluded FDG-PET/CT being
a useful, accurate tool for establishing the diagnosis of
large-vessel vasculitis, for evaluating disease extension, and
for monitoring therapy in conjunction with clinical and
biochemical findings [10].
More recently, Henes et al. retrospectively studied 10
patients with proven vasculitis that were treated with
cyclophosphamide, because they were not responding to
corticosteroids and/or had organ or limb threatening vascular
stenosis. FDG-PET/CT was performed before and during
(6 out of 10 cycles mostly) therapy and the visual grading
score of Meller was used. Before therapy, the grading score
was 3 in 8 patients and 2 in 2 patients. During therapy, all
patients had a grading score equal to or lower than 2. Nine
out of 10 patients showed clinically a complete remission after
10 cycles of cyclophosphamide. The authors concluded that
cyclophosphamide was an effective therapy in patients and
that FDG-PET/CT might serve in future as an additional
tool to continue successful treatment or stop the unsuccessful
[23].
FDG-PET/CT was also found to have impact on the
clinicalmanagement in a significant proportion of 30 patients
with suspected GCA, both in patients without and already
with immunosuppressive medication. The addition of FDG-
PET increased the number of indicated biopsies and changed
treatment recommendation in 27% of patients [24].
3. Sarcoidosis
3.1. FDG-PET/CT and Classification of Sarcoidosis. Sarcoido-
sis is a multisystem granulomatous disease that affects pre-
dominantly the lungs and associated lymph nodes but may
involve virtually any organ. Despite the progress in imaging
techniques, only one imaging classification system exists that
was already describedmore than 4 decades ago [25].This sys-
tem classifies chest radiographic findings as stage 0 (normal
radiography), stage I (bilateral hilar lymphadenopathy), stage
II (stage I and parenchymal infiltration), stage III (parenchy-
mal infiltration without hilar lymphadenopathy), and stage
IV (parenchymal infiltration with pulmonary fibrosis) [26].
Of course, this classification system is obsolete, because of the
currently existing imaging modalities.
For conventional imaging, high resolution computed
tomography (HRCT) is now widely accepted as the radio-
graphic imaging reference standard in the evaluation of
sarcoidosis and other diffuse infiltrative lung diseases [27].
HRCT is superior to conventional CT in delineating the
distribution and pattern of pulmonary interstitial lesions [26]
and has typical findings for sarcoidosis with small nodules
in perilymphatic distribution or along fissures but also with
alveolar consolidationwith air bronchograms, cavitation, and
fibrosis when there is lung involvement. Sensitivities reported
for HRCT in diffuse infiltrative lung diseases are high (>90%)
[28]; however, it is often difficult to differentiate sarcoidosis
from other interstitial diseases, and biopsy is still required.
FDG-PET provides valuable information in this disease
as FDG is highly taken up by the granulomas. Moreover,
whole body imaging is possible with FDG-PET. Different
presentations of sarcoidosis on FDG-PET exist. Keijsers et
al. categorized FDG-PET patterns in sarcoidosis patients
based on the presence and extent of organ involvement. The
involvement of thoracic lymph nodes and lung parenchyma









Figure 2: FDG-PET classification of sarcoidosis. Type I: thoracic lymph node involvement (in this image: mediastinal and hilar regions),
type II: involvement of the lung parenchyma, type III: diffuse lymph node involvement (in this image all lymph node regions of the body are
involved), and type IV: organ involvement (in this image involvement of the spleen and bones) (images courtesy by R. Keijsers).
was considered as the presence of extrathoracic disease
(Figure 2). This system could have added value for prognosis
and stratification as parenchymal disease, splenomegaly, and
involvement of more than three organ systems is associated
with a poor prognosis [29, 30].
For diagnosis, both FDG-PET and HRCT are necessary.
HRCT is required because of its typical findings for sar-
coidosis, as mentioned earlier, and because FDG-PET is not
very specific: the uptake pattern in sarcoidosis can mimic
malignancy or lymphomadisease. Despite this low specificity,
FDG-PET has been extensively studied on a relatively large
number of patients, andmany publications support the use of
FDG-PET for diagnosis, although in combination with (HR)
CT.
FDG-PET has a high sensitivity for diagnosing sarcoido-
sis, and provides valuable information to evaluate pulmonary
and extrapulmonary sarcoidosis [2]. Whole body FDG-PET
imaging may uncover an occult diagnostic site or multiple
organ involvement [31] and is also useful in cardiac [32] and
cerebral [33] sarcoidosis. Compared with the old “gold
standard” tracer for sarcoidosis, 67Ga-citrate SPECT, FDG-
PET was found more suitable for imaging the mediastinum,
the hilar lymph nodes, the posterior regions of the lungs, and
nonthoracic lesions [34, 35].Themetabolic activity measured
with FDG-PET reflects the disease activity in sarcoidosis
in quantitative terms and the SUVmax correlates with his-
topathological results from bronchoalveolar lavage [36]. Dif-
fuse parenchymal uptake of FDG predicts a future deteriora-
tion—when untreated—of the diffusion capacity of the lung
and absence of activity in the lung parenchyma could justify a
wait-and-see policy [37]. Furthermore, FDG-PET may show
some specific features that could help in the diagnosis, for
example, thick linear FDG uptake in the lower legs in mus-
cular sarcoidosis (the so-called “tiger man” sign) [38].
3.2. FDG-PET/CT and Therapy Evaluation. For treatment of
sarcoidosis, several options are possible: treatmentwith corti-
costeroids in various doses, antimalarial drugs such as hy-
droxychloroquine, cytotoxic drugs, and also with cytokine
modulating drugs, such as infliximab or adalimumab, both
being antitumor necrosis factor alpha (anti-TNF𝛼) antibod-
ies.
Again, there is arguable evidence in the literature: FDG-
PET/CT is a valuable imaging tool in assessing treatment
efficacy in patients with sarcoidosis and deciding whether
to switch to an alternate therapeutic regimen [31, 39–42]
(Figure 3). Almost all patients in these studies were treated
with corticosteroids, which resulted in a decrease in uptake
on FDG-PET but also in clinical and biochemical improve-
ment.
One study performed FDG-PET/CT before and after 6
cycles of infliximab therapy in 12 patients with refractory
sarcoidosis (not reacting on corticosteroid therapy). Clini-
cal improvement was seen in all patients, although minor
response in one. FDG-PET improvement or normalization
was seen in 11 of the patients with an overall decrease in
SUVmax of 55%. However, the patient with a minor clinical
response showed a 34% increase in FDGuptake [43].Wemay
conclude from this study that FDG-PET/CT is not only useful
to assess the efficacy of corticosteroid therapy butmay also be
useful in other therapies, such as infliximab.
4. Autoimmune Diseases
4.1. Rheumatoid Arthritis. Rheumatoid arthritis (RA) is an
autoimmune disease, which is associated with systemic and
chronic inflammation of the joints, resulting in synovitis and
pannus formation, both leading to increased FDG uptake.
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Figure 3: An example of the value of FDG-PET/CT in a patient with sarcoidosis: (a) baseline scan, (b) scan after 3 months of corticosteroid
therapywith progression of lung infiltration, and (c) scan after 3months of treatmentwith corticosteroids andmethotrexate together, resulting
in complete remission (the linear uptake is located in a muscle in the back and considered physiological muscle uptake).
Several clinical studies evaluated the role of FDG-PET in
patients with RA [44–46]. The degree of FDG uptake in
affected joints reflects the disease activity of RA [47] and
correlates with clinical parameters, including the disease
activity score (DAS), swelling and tenderness, ultrasonog-
raphy (US) findings for synovitis and synovial thickening,
power Doppler studies for neovascularization, ESR, and CRP
[48]. FDG-PET was eligible to identify joints with active
RA with higher sensitivity than clinical symptoms [47]. The
quantification of metabolic changes in joint inflammation
with FDG-PET was comparable to volumetric changes visu-
alized withMRI. However, bothMRI and FDG-PETwere not
associated with treatment outcome [48].
For therapy evaluation, studies are scarce. Beckers et al.
assessed 16 patients with active RA in the knee joint using
FDG-PET, dynamic MRI, and US at baseline and four weeks
after the initiation of anti-TNF𝛼 treatment. Significant differ-
ences in theMRI and US findings were observed between the
FDG-PET positive and FDG-PET negative patients. Changes
in the SUV after four weeks were correlated with changes in
the MRI parameters, but not with the changes in synovial
thickness observed by US [49]. This suggests metabolic
changes are preceding morphological changes in patients
with RA.
Goerres et al. used a visual assessment total joint score,
that is, the sum of all scores based on FDG uptake intensity
between zero and four in 28 joints, in seven patients with
active RA before and after infliximab treatment. The reduc-
tion of FDG joint uptake in the follow-up scans correlated
significantly with clinical evaluation of disease activity [50].
Recently, an association was found between changes in
FDG joint uptake between baseline and after two weeks of
infliximab treatment and the clinical outcome on long term.
Changes in the mean SUV between the baseline scan and the
scan after twoweeks of treatment correlated significantlywith
the DAS at 14 and 22 weeks and contributed significantly to
the prediction of DAS at these time points. So, early changes
in FDG uptake in joints during infliximab treatment may
predict clinical outcome [51].
These current collected data together deliver not enough
evidence to support the use of FDG-PET for the routine use
in patients with RA. In the recently published EULAR recom-
mendation for the use of imaging of the joints in the clinical
management of RA, FDG-PET was not recommended as an
imaging tool, neither for diagnosis nor for therapy evaluation
[52]. To better define the role of FDG-PET in patients with
RA, larger patient studies are warranted to understand the
clinical usefulness of this technique in this setting.
4.2. Inflammatory Bowel Diseases. Inflammatory bowel dis-
eases (IBD) are represented mainly by ulcerative colitis
(UC) and Crohn’s disease (CD) and characterized by a
chronic, uncontrolled inflammation of the intestinal mucosa.
Reported studies in the literature about the use of FDG-
PET in IBD—although few in number—concluded that
this imaging modality holds potential in evaluating disease
activity and providing an objective assessment of the severity
of bowel inflammation. Despite these findings, overall not
enough literature has been published to support a role for
FDG-PET for diagnostic purposes [40, 53]. FDG-PET cor-
relates globally well with clinical activity scores and may be
useful when conventional imaging fails to yield a conclusive
diagnosis [54]. Despite MRI being the technique of choice in
children [55, 56], FDG-PET was found especially suitable for
the assessment of IBD in children, where it detected inflamed
gut segments with high sensitivity and specificity [57] and
could be useful as a noninvasive tool in the followup of
children with known chronic IBD, where a yearly invasive
colonoscopy is not desirable [58] An example is shown in
Figure 4. In another study, the clinical utility of FDG-PET/CT
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Figure 4: A 14-year-old girl known with Crohn’s disease. FDG-PET/CT (left: MIP image of the FDG-PET, right: fused FDG-PET/CT
transaxial slice) showed inflammation of the caecum.
was compared to the standardworkup in patients with known
or suspected IBD and found very useful, not only in diagnosis
but also in therapy management. In this study, unnecessary
disease escalation or initiation of IBD therapy was avoided
based on the PET/CT results [59].
Despite all these positive results, a major limitation of
the use of FDG in IBD is that in a lot of patients gradual
physiological uptake in the bowel can be seen, especially in
the large bowel, which may create problems in diagnosing
IBD in colonic segments. Bowel movements during the
scan acquisition can blur the images. Furthermore, diabetic
patients who take antidiabetic drugs (e.g., metformin) may
show intense uptake in the large bowel. To solve these
problems, maybe FDG-PET/CT colonography offers a novel
technique for the assessment of extent and activity of IBD.
In this technique, the colon is inflated with oral ingestion
of polyethylene glycol before acquiring images. In a pilot
study in 15 patients, a good correlation was found between
PET activity grades after PET/CT colonography and the
endoscopic grade of inflammation [60].
Aside from the diagnostic use of FDG, its main utility
in IBD can be the early evaluation of treatment success.
Indeed FDG represents the whole inflammatory burden of
the gut, and an early posttherapy scan (within weeks of
beginning of therapy) comparedwith a pretherapy scan could
allow the evaluation of therapy efficacy. To this aim, the
only published study is in a small group of 5 patients. FDG-
PET/CT was performed in these patients before and after
successful medical therapy in patients with moderately active
IBD. Five bowel segments were scored on a 0–3 scale (0
= no uptake or uptake lower than liver, 1 = equal to liver,
2 = greater than liver, and 3 = three times liver uptake
or higher) for the appropriate FDG-PET assessment. The
total score of all segments was 32 before treatment and 14
after treatment. Of 11 pretreatment active segments (score
2 or 3), nine (82%) segments either became inactive or
displayed decreased activity, while two showed no change.
These findings correlated with clinical symptoms [61]. One
major limitation of this study, however, was the time point of
the FDG-PET/CT after therapy, this ranged from 77 to 807
days after the baseline scan.
Taken together, all these findings about the use of FDG-
PET/CT in IBD demonstrate that currently there are no large
patient studies to support the use of this imaging technique
for diagnosis and therapy evaluation.This was confirmed in a
recently published meta-analysis [62]. However, considering
the potential in evaluating disease activity, FDG-PET/CT
may have a role to evaluate therapy in IBD in future.
4.3. Autoimmune Thyroiditis. Several forms of autoimmune
thyroiditis (AIT) exist, the most important being Riedel’s
thyroiditis, characterized by a replacement of the normal
thyroid parenchyma by a dense fibrosis that invades adjacent
structures of the neck and may extend beyond the thyroid
capsule, and Hashimoto’s thyroiditis (also called lymphocytic
thyroiditis), in which the thyroid gland is gradually destroyed
by a variety of cell- and antibody-mediated immune pro-
cesses. AIT can result—on short or longer term—in hypothy-
roidism.
Normally, uptake of FDG in thyroid tissue is low or
absent and unexpected findings in the thyroid gland fall
into 2 categories: focal or diffusely increased uptake of FDG.
Diffusely increased uptake of FDG in the thyroid is thought
to be associated with AIT or hypothyroidism [63] and is
mentioned in several case reports [64–66]. In contrast, other
authors mention that only 9.5% of PET scans in patients with
hypothyroidism as a result of Hashimoto’s thyroiditis display
diffuse thyroid activity [67].
For the use of FDG-PET as an aid in the followup in
Riedel’s thyroiditis, Kotilainen et al. describe a 60% decrease
in the FDG uptake in the thyroid in the follow-up PET after
two weeks of treatment with corticosteroids, indicating that
FDG metabolic activity can also be used to assess a patient’s
response to therapy in Riedel’s thyroiditis [68].
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One important large retrospective study mentioned dif-
ferent findings. Of 4,732 investigated FDG-PET/CT scans,
138 (2.9%) showed diffuse thyroid uptake. In 47%, a prior
diagnosis of hypothyroidism or AIT was found, of whom
the majority received thyroxin therapy. In a control group
without thyroid uptake, 10%had a prior diagnosis of hypothy-
roidism and received therapy for that. Of the remaining
patients with diffuse thyroid uptake, 32 were examined for
thyroid diseases after the findings on the FDG-PET, of which
19 were found to have AIT or hypothyroidism. So, diffusely
increased FDG uptake in the thyroid is associated with AIT,
but uptake seems not to be affected by hormonal therapy.
Furthermore, no correlation was found between SUV and the
degree of hypothyroidism [63].
At the moment, there is no special role for FDG-PET/CT,
neither in diagnosing AIT nor in evaluating treatment effi-
cacy.
4.4. Autoimmune Pancreatitis. Autoimmune pancreatitis
(AIP) is a subset of pancreatitis characterized by enlargement
of the pancreatic parenchyma and irregular narrowing of the
main pancreatic duct, caused by an autoimmune inflam-
matory process with prominent lymphoplasmacytic infiltra-
tion and fibrosis of the pancreas [69].
FDG-PET/CT imaging findings in patients with AIP
have been explored in a small number of studies. FDG-PET
was found to be useful for detecting AIP and associated
extra pancreatic autoimmune lesions and also for monitoring
disease activity [70–73]. These studies were performed in
small numbers of patients, so larger patient studies are def-
initely warranted.
Another important message is the ability of FDG-
PET/CT to differentiate between AIP and pancreatic cancer.
Reported sensitivities for pancreatic cancer vary between 72
and 96%, the latter result achieved together with contrast-
enhancedCT [74, 75]. ForAIP, published studies are too small
to calculate sensitivity and specificity. Both conditions nor-
mally accumulate FDG, so FDG-PET/CT cannot always dis-
criminate between the two conditions. However, by looking
carefully at the pattern of FDG accumulation, accompanying
other autoimmune diseases, and the change in FDG uptake
after steroid treatment, it may be possible to differentiate
between both diseases on the short term. At baseline, FDG-
PET shows more diffuse uptake in the pancreas in AIP
compared to the more focally located lesions in pancreatic
cancer. The detection of other autoimmune diseases, such
as uptake in the salivary glands (sclerosing sialadenitis), in
the thyroid (AIT) and in the bile ducts (cholangitis), also
points towards the diagnosis AIP. Furthermore, a decrease in
pancreatic uptake after a short period of steroid therapy (two
weeks) may be useful for discriminating AIP from pancreatic
cancer [76, 77].
Larger patient studies are necessary to clarify the useful-
ness of FDG-PET/CT in diagnosis and therapy monitoring.
However, when having a diagnostic dilemma between AIP
and pancreatic cancer, orwhen biopsy is not feasible, the FDG
uptake pattern and decrease of FDG uptake on the follow-up
scan after a short period of therapy, may help to solve this
clinical problem.
5. Osteomyelitis
The quick identification and precise localization of osteo-
myelitis (OM) is critical for early initiation of antimicrobial
and/or surgical treatment and has a significant impact on
patient outcome [78]. FDG-PET/CT has been evaluated in
patients with primary OM extensively, has been shown to
offer good sensitivity (>95%) and specificities above 87%
[79], and was found superior to MRI [80] and other nuclear
medicine imaging modalities [81]. However, used in combi-
nation with conventional methods, FDG-PET/CT may have
limited additional value in the diagnosis of primary OM.
In contrast, FDG-PET/CT may play an important role in
patients with chronic OM, especially in those patients with
previously documented OM and suspected recurrence, or
presenting with symptoms of OM for more than six weeks
(chronic OM) [3]. In children with suspected OM, dissemi-
nation in multiple bones has to be kept in mind, for which
FDG-PET/CTwould be suitable. However, to avoid radiation
exposure, pediatricians tend to perform MRI rather than
FDG-PET/CT in cases of suspected OM [82].
For therapy evaluation in patients with OM, the literature
results are hopeful. In a recent retrospective study, FDG-
PET/CT had a strong impact on the clinical management
(initiation or prolongation of antibiotic therapy or recourse
to surgical intervention) in 52% of patients with an infection
[83]. Gemmel et al. highlighted the clinical role of FDG-
PET/CT in the diagnosis of spinal infections, especially in
patients with contraindications to MRI, and in evaluation
of the postoperative spine [84]. Worth to mention is that in
MRI inflammatory changes can be seen long after the disap-
pearance of the infection. For this indication, FDG-PET
is probably superior to MRI. In children, FDG-PET/CT
was found superior in distinguishing between infection and
reparative activity within the musculoskeletal system after
treatment for acute OM, and termination of antibiotic treat-
ment for children after acute OM seems justified when labo-
ratory parameters and clinical parameters are normal, and
FDG-PET/CT is unsuspicious [85].
Despite these results, major limitations exist for the use of
FDG-PET/CT in some infectious bone diseases. In general, in
patients with infections or inflammation, the bonemarrow, at
various levels, can show increased uptake. In prosthetic joint
infections (PJI), the problem is the generation of artifacts,
characterized by artificial FDGuptake adjacent to prostheses,
because of the inherent problem of partial volume mapping
and overcorrection. In PJI, white blood cell scintigraphy is
still the first choice [86]. Further on, nonspecific FDG uptake
may be seen in healing tissues, up to 6 months after surgical
intervention [87]. In the diabetic foot, FDG-PET/CT was
found to have a low diagnostic accuracy for OM and cannot
replace white blood cell scintigraphy [88].
At this moment, evidence-based indications for FDG-
PET/CT are primary peripheral bone OM (not post-
operative, not in diabetic foot) and suspected spinal infection
(spondylodiscitis or vertebral OM, not postoperative; see
Figure 5) [89]. In the future, one can expect that FDG-
PET/CT will also be used to monitor treatment efficacy, and
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Figure 5: FDG-PET of a patient with spondylodiscitis and involvement of the psoasmuscles. (a) CoronalMIP view, (b) fused PET/CT sagittal
view, and (c) fused PET/CT transaxial view.
maybe this technique can provide criteria to decide when the
treatment can be stopped safely.
6. Fungal Infections
Fungal infections can develop in patients who are taking
antibiotics for a long time period (due to an altered balance
of microorganisms in the body and an overgrowth of fungus)
and in patients with a suppressed immune system, for
example, HIV/AIDS, steroid treatment, and chemotherapy.
In daily practice, FDG-PET/CT has been used already for
many years in various fungal infections, such as aspergillosis,
candidiasis, histoplasmosis, coccidioidomycosis, cryptococ-
cosis, and Pneumocystis jiroveci [90–96]. However, systemic
investigations of use of FDG-PET/CT in patients with fungal
infections are virtually absent. In the majority, these infec-
tionswere found by coincidence in patients that were scanned
for other reasons. The largest study in diagnosing fungal
infections was published by Chamilos et al., who reported
their own experiences in 13 patients, together with the results
of nine case reports in the literature. Most patients had
an underlying malignancy (73%), primarily of hematolog-
ical origin, and seven were allogeneic hematopoietic stem
cell transplant recipients. FDG-PET frequently found occult
lesions that were not found with other imaging techniques,
and the results helped to determine treatment length in eight
of these 16 patients. Overall, FDG-PET was helpful in 60% of
the patients [97].
The role of FDG-PET in monitoring therapeutic efficacy
has also been described in the setting of invasive aspergillo-
sis, chronic disseminated candidiasis, candidal lung abscess
following antifungal therapy, and Pneumocystis carinii pneu-
monia, all with good results [98–100].
In our opinion, FDG-PET/CT offers a unique possibility
in the monitoring of therapy efficacy in patients with fungal
infections. Antifungal therapy is extensive and must be
prolonged for a long time, sometimes even for months. FDG-
PET/CT could help to decide whether therapy should be
continued, stopped, or switched. An example is given in
Figure 6.
7. Guidelines
Recently, combined guidelines from the European Associa-
tion of NuclearMedicine (EANM) and the Society of Nuclear
Medicine and Molecular Imaging (SNMMI) were published
for the use of FDG-PET in inflammation and infection [89].
Based on cumulated reported accuracies, >85% of these
guidelines state that the major indications for the use of
FDG-PET/CT in infection and inflammation are sarcoidosis,
peripheral bone osteomyelitis, spondylodiscitis, evaluation
of fever of unknown origin, and the primary evaluation
of vasculitis. Other well-described applications, however, at
this time-pointwithout sufficient evidence-based indications,
are the evaluation of potentially infected liver and kidney
cysts, suspected infection of intravascular devices, AIDS-
associated opportunistic infections, and the assessment of
metabolic activity in tuberculosis lesions. For inflammatory
bowel diseases, it is unclear if FDG-PET/CT offers advan-
tages over other imaging techniques. The guidelines do not
describe the role of FDG-PET/CT for the other described
applications in this paper (rheumatoid arthritis, autoimmune
thyroiditis, autoimmune pancreatitis, and fungal infections).
To our opinion, however not stated in the literature yet,
FDG-PET/CT could also have additional value in rheumatoid
arthritis and fungal infections.
8. Comparison with Other Tracers
In this paper, we focused only on FDG-PET. To emphasize,
one should keep in mind that FDG merely detects glu-
cose metabolism and is therefore not able to discriminate
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Diagnosis + I-A Differentiation possible between GCA,TA, and PAN∗
Therapy evaluation + I-C Best time point at 3 months
Sarcoidosis
Diagnosis + I-A High sensitivity, low specificity
Therapy evaluation + I-C To evaluate steroid therapy; maybealso for other therapies
Rheumatoid arthritis
Diagnosis + + IIa-C
Therapy evaluation + + IIa-C
Inflammatory bowel
diseases Especially in children
Diagnosis + I-C
Therapy evaluation + + IIa-C
Autoimmune thyroiditis
Diagnosis − III-B
Therapy evaluation − III-B
Autoimmune pancreatitis
Diagnosis + + IIa-C Maybe possible to differentiatebetween AIP and pancreatic cancer
Therapy evaluation + + IIb-C
Osteomyelitis
Diagnosis + I-A Only in chronic osteomyelitis
Therapy evaluation + + IIa-C
Spondylodiscitis
Diagnosis + I-A
Therapy evaluation + + IIa-C
Prosthetic joint infections
Diagnosis − + IIb-C White blood cell scintigraphy still thefirst choice
Therapy evaluation − + IIb-C
Diabetic foot
Diagnosis − + IIb-C White blood cell scintigraphy still thefirst choice
Therapy evaluation − + IIb-C
Echinococcosis
Diagnosis + I-C
Therapy evaluation + I-C
Fungal infections
Diagnosis + I-C
Therapy evaluation + + IIa-C Maybe helpful to reduce high costs ofantifungal therapy
∗GCA: giant cell arteritis; TA: Takayasu’s arteritis; PAN: polyarteritis nodosa.
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Figure 6: FDG-PETof a neutropenic patient (due to leukemia)with a fungal infection (aspergillosis) before (left image) and during antifungal
therapy (right image) resulting in a decrease in FDG uptake in the lung lesions. Because on the last FDG-PET scan (right image) there is still
no complete remission, the patient is still treated with antifungal drugs.
between infection, inflammation, and neoplastic disease.
Consequently, there is lack of specificity in some indica-
tions, especially in sarcoidosis. Many other, more specific
tracers, targeting specific cells and molecules involved in a
specific disease, are developed and investigated. These objec-
tive biomarkers are used for histological characterization
of inflammatory lesions (specific receptor expression), for
selection of patients for receptor-targeted therapy (overex-
pression of a specific receptor), and for therapy response
prediction and followup (intensity of receptor expression
and its modulation). Other articles are available that provide
an overview of all the tracers used for inflammatory and
infectious diseases [2].
9. Conclusions
This paper provides an overview of the use of FDG-PET/CT
in various infectious and inflammatory diseases, not only in
the setting of diagnosis but also in the evaluation of treatment
efficacy (see Table 1). For vasculitis, sarcoidosis, and spondy-
lodiscitis, scientific evidence indicates that FDG-PET/CT is
useful for diagnosis and for therapy evaluation. For other
diseases, such as inflammatory bowel diseases, rheumatoid
arthritis, autoimmune pancreatitis, osteomyelitis, prosthetic
joint infection, and fungal infections, a strong evidence is
lacking. Only for autoimmune thyroiditis there is lack of
evidence, and therefore, FDG-PET/CT should not be used in
this setting.
In any case where FDG can be used for therapy followup,
a pretherapy scan is of relevance to compare it with the
posttherapy scan.
As it is a repeating problem in nuclear medicine, that no
large patient studies are available in the literature to give final
answers, we want to stress the importance to start prospective
large multicenter studies to provide evidence-based answers.
This is not only important in the era of our own imaging field
but may also prove to be cost effective as anti-inflammatory
therapies are in general expensive.
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